{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:28:46Z","timestamp":1792812526474,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Venous thromboembolism (VTE) poses a significant global health challenge, notably exacerbated by the use of combined oral contraceptives (COCs). Evidence mainly focuses on the type of progestogen used in COCs to establish the increased risk of VTE with less data assessed on the type of estrogen used. This meta-analysis aims to assess the risk of VTE associated with COCs containing synthetic estrogens like ethinylestradiol (EE) versus natural estrogens like estradiol (E2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review and meta-analysis was conducted following the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Literature searches were performed in December 2023 in MEDLINE and EMBASE to identify clinical studies comparing the VTE risk between COCs containing synthetic versus natural estrogens. Studies were selected through rigorous screening, and data extraction followed standardized protocols, with statistical analyses employing a random effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The search yielded five relevant studies, involving over 560,000 women\/time, demonstrating a significant 33% reduction in VTE risk among users of natural estrogen-based COCs compared to synthetic estrogen-based COCs (OR 0.67, 95% CI 0.51\u20130.87). Stratification analyses using adjusted hazard ratios (HR) of the main observationnal studies showed a 49% reduced VTE risk of E2-based pills compared to EE in association with levonorgestrel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusion<\/jats:title><jats:p>Despite the longstanding use of EE-based COCs, emerging evidence supports a lower thrombotic risk associated with natural estrogens. This meta-analysis substantiates the lower VTE risk associated with natural estrogen-based COCs compared to synthetic alternatives, advocating for a re-evaluation of contraceptive guidelines to prioritize patient safety and reduce thrombotic risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1428597","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:46:06Z","timestamp":1723783566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jonathan","family":"Douxfils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Didembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Morimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"Gerard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B4","volume-title":"Assessment report for combined hormonal contraceptives containing medicinal products \u2014 Procedure number: EMEA\/H\/A-31\/1356","year":"2014"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714140","article-title":"Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk","volume":"46","author":"Douxfils","year":"2020","journal-title":"Semin Thromb hemostasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD010813","DOI":"10.1002\/14651858.CD010813.pub2","article-title":"Combined oral contraceptives: venous thrombosis","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev 2014"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"B8","volume-title":"Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints - CHC-CVD final report 111022v2","year":"2011"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2014.01.023","article-title":"Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives","volume":"89","author":"Dinger","year":"2014","journal-title":"Contraception"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2016.01.012","article-title":"Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives","volume":"93","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17beta-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"B14","volume-title":"FSRH Guideline - Combined Hormonal Contraception (amended October 2023)","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","first-page":"360 e1","DOI":"10.1016\/j.ajog.2023.09.012","article-title":"The risk of venous thromboembolism in oral contraceptive users: the role of genetic factors-a prospective cohort study of 240,000 women in the UK Biobank","volume":"230","author":"Lo Faro","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.rpth.2023.100155","article-title":"Hormonal therapies and venous thrombosis: considerations for prevention and management-a reappraisal","volume":"7","author":"Douxfils","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.rpth.2022.100021","article-title":"Hormonal therapies and venous thrombosis: Estrogen matters","volume":"7","author":"Morimont","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17beta-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"Gaussem","year":"2011","journal-title":"Thromb haemostasis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"Klipping","year":"2011","journal-title":"Drugs R&D"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous thromboembolic risk of estradiol valerate-dienogest compared with ethinyl estradiol-levonorgestrel combined oral contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet Gynecol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14384","article-title":"Systemic hormonal contraception and risk of venous thromboembolism","volume":"101","author":"Heikinheimo","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17268","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data","volume":"129","author":"Schink","year":"2022","journal-title":"BJOG"},{"key":"B26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B27","article-title":"Chapter 10: Analysing data and undertaking meta-analyses. Version 6.4 (updated August 2023)","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2023"},{"key":"B28","article-title":"FCS29.3.Final results from the INAS-score study \u2013 VTE and ATE Risk in users of different combined oral contraceptives","author":"Bardenheuer","year":"2015"},{"key":"B29","article-title":"FCS501 | Cardiovascular safety of different combined oral contraceptives \u2013 final INAS score study results","author":"Heinemann","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2017.07.114","article-title":"Cardiovascular safety among users of different combined oral contraceptives \u2014 final results from the INAS-SCORE study","volume":"96","author":"Heinemann","year":"2017","journal-title":"Contraception"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2166032","DOI":"10.1080\/09513590.2023.2166032","article-title":"NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study","volume":"39","author":"von Stockum","year":"2023","journal-title":"Gynecol Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pds","article-title":"Cardiovascular safety in users of different combined oral contraceptives\u2014final results from the INAS-score study","volume":"24","author":"Bardenheuer","year":"2015","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0149-8","article-title":"Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals","volume":"37","author":"Gourbil","year":"2014","journal-title":"Drug Saf"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.15761\/FWH","article-title":"Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study","author":"Dinger","year":"2020","journal-title":"Front Women\u2019s Health 5"},{"key":"B35","article-title":"FC3-19 Thrombotic diseases in users\u00a0of\u00a0estradiol\/dienogest oral contraceptives: a historical national follow-up study 2009 \u2013 2011","author":"Lidegaard","year":"2013"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"Agren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"Bmj"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"Bmj"},{"key":"B39","doi-asserted-by":"publisher","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"Bmj"},{"key":"B40","doi-asserted-by":"publisher","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"Bmj"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et\u00a0al. entitled \"Estrogen and thrombosis: A bench to bedside review\" (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2015.1050091","article-title":"Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review","volume":"20","author":"Lete","year":"2015","journal-title":". Eur J Contracept Reprod Health Care"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.15761\/FWH","article-title":"COCs containing dienogest and 30 \u00b5g ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies","volume":"5","author":"Dinger","year":"2020","journal-title":"Front Women\u2019s Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab medicine: CCLM \/ FESCC"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2023.128815","article-title":"Response to paper by Binkowska et\u00a0al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy","volume":"22","author":"Douxfils","year":"2023","journal-title":"Prz Menopauzalny"},{"key":"B46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG"},{"key":"B47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.thromres.2018.03.005","article-title":"Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose","volume":"165","author":"Oedingen","year":"2018","journal-title":"Thromb Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2019.02.001","article-title":"Segesterone acetate\/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation","volume":"99","author":"Gemzell-Danielsson","year":"2019","journal-title":"Contraception"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:46:12Z","timestamp":1723783572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":50,"alternative-id":["10.3389\/fendo.2024.1428597"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1428597","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"article-number":"1428597"}}